Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Palatin Technologies logo — We discover and develop novel therapeutics for patients livi...

Palatin Technologies

We discover and develop novel therapeutics for patients living with inflammatory and autoimmune conditions.

Founded 1986 50 employees Post Ipo Equity Total: $133.90M Biotechnology, Health Care +1

General Information

Company Name Palatin Technologies
Founded Year 1986
Founders / Decision Makers
Team member Team member
Employees 50
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Post Ipo Equity
Social

Get notified when Palatin Technologies moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Palatin Technologies

Palatin Technologies is a biopharmaceutical company focused on developing innovative therapeutics for patients with inflammatory and autoimmune conditions. The company's successful FDA approval of Vyleesi®, a treatment for women with hypoactive sexual desire disorder (HSDD), demonstrates its expertise in the development of melanocortin-based therapeutics. Palatin is now directing its efforts towards leveraging the melanocortin system to address harmful inflammation in conditions affecting the eye, gastrointestinal system, and kidney. The company's leading ocular product, PL9643, designed to treat dry eye disease, is poised to enter Phase 3 clinical trials in the second half of 2021. Additionally, Palatin is advancing therapeutics for ophthalmic indications such as non-infectious uveitis, retinopathies, and corneal diseases. With plans for proof of concept clinical studies in ulcerative colitis and kidney disease, Palatin aims to demonstrate the broad utility of melanocortin system-modulating therapeutics. Vyleesi® stands out as the first and only on-demand, FDA-approved treatment for premenopausal women with HSDD, a condition affecting 1 in 10 pre-menopausal women. Palatin's commitment to positively impacting patient lives and creating value for shareholders is exemplified through its therapeutic programs and milestones in the biotechnology and healthcare industries. For further information on Palatin Technologies and its programs, visit www.palatin.com.

Taxonomy: biopharmaceutical, therapeutics, medical research, melanocortin system, inflammatory conditions, autoimmune conditions, ophthalmic indications, clinical trials, FDA approval, premenopausal women's health, inflammatory disease treatment, drug development, investor relations, clinical studies

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 30 Jan 2024
Post-IPO Equity •••••• - 23 Oct 2023
Grant •••••• 1
Investor
18 Jan 2023
Post-IPO Equity •••••• - 31 Oct 2022
Post-IPO Equity •••••• - 08 Dec 2016

View All 9 Funding Rounds

Palatin Technologies Alternatives & Competitors

Palatin Technologies vs
VYNE Therapeutics Inc.
VYNE Therapeutics Inc. United States

For every therapeutic challenge, we question traditional assumptions and find better solutions.

Post Ipo Equity
52 employees
Health Care, Health and Wellness
Compare Palatin Technologies vs VYNE Therapeutics Inc.
Palatin Technologies vs
Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc. Canada

Life sciences company focused on the research and clinical development of therapies for the treatmen...

Post Ipo Equity
27 employees
Biotechnology, Life Sciences
Compare Palatin Technologies vs Cardiol Therapeutics Inc.
Palatin Technologies vs
Nordic Bioscience
Nordic Bioscience Denmark

Improving preclinical and clinical trial success rates with world-leading biomarkers & specialized l...

Private Equity
224 employees
Biotechnology, Health Care
Compare Palatin Technologies vs Nordic Bioscience
Also compare with: Palatin Technologies vs NRC Research Institute NRC Research Institute

FAQ About Palatin Technologies

We discover and develop novel therapeutics for patients living with inflammatory and autoimmune conditions.
Palatin Technologies was founded in 1986.
Palatin Technologies operates in the following industries: Biotechnology, Health Care, Health and Wellness.
Palatin Technologies has approximately 50 employees.
Palatin Technologies has completed 9 funding rounds, raising a total of $133.90M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Palatin Technologies include VYNE Therapeutics Inc., Cardiol Therapeutics Inc. , Nordic Bioscience, SyneuRx International (Taiwan) Corp., NRC Research Institute . These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Palatin Technologies and VYNE Therapeutics Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Palatin Technologies and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy